ReviewJournal of thoracic disease2018
Latest development of liquid biopsy.
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis.Cancer medicine · 2020Pooled it
- Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.International journal of molecular sciences · 2018Pooled it
- Translational Insights into NK Immunophenotyping: Comparative Surface Marker Analysis and Circulating Immune Cell Profiling in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients.Journal of translational medicine · 2025Article
- Cancer Cell Line Classification Using Raman Spectroscopy of Cancer-Derived Exosomes and Machine Learning.Analytical chemistry · 2025Article
- SERS and Machine Learning-Enabled Liquid Biopsy: A Promising Tool for Early Detection and Recurrence Prediction in Acute Leukemia.ACS omega · 2025Article
- The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases.Journal of molecular neuroscience : MN · 2025Review
- Knowledge-Informed Machine Learning for Cancer Diagnosis and Prognosis: A Review.IEEE transactions on automation science and engineering : a publication of the IEEE Robotics and Automation Society · 2025Article
- Advancements in precision oncology: Investigating the function of circulating DNA in the advancement of liquid biopsy technologies.The journal of liquid biopsy · 2024Article
- The Future of Kawasaki Disease Diagnosis: Liquid Biopsy May Hold the Key.International journal of molecular sciences · 2024Review
- The Interplay between Glioblastoma Cells and Tumor Microenvironment: New Perspectives for Early Diagnosis and Targeted Cancer Therapy.Brain sciences · 2024Review
- Small extracellular vesicles promote the formation of the pre-metastatic niche through multiple mechanisms in colorectal cancer.Cell cycle (Georgetown, Tex.) · 2024Review
- The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNAJTO clinical and research reports · 2024Article
- Biopsy of bone tumors: a literature review.Revista da Associacao Medica Brasileira (1992) · 2024Review
- Exosomes as Powerful Biomarkers in Cancer: Recent Advances in Isolation and Detection Techniques.International journal of nanomedicine · 2024Review
- Optimal Parameter Configuration of a Microfluidic Chip for High-Throughput, Label-Free Circulating Tumor Cell Separation and Enrichment Based on Inertial Focusing.Diagnostics (Basel, Switzerland) · 2023Article
- Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer.Cancers · 2023Review
- Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer.Scientific reports · 2023Article
- Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis.Medical oncology (Northwood, London, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy provides the opportunity of detecting and analyzing cancer in various body fluids. In peripheral blood, apart from circulating cell free DNA, circulating cancer cells and other tumor-associated compounds such as extracellular vesicles are also emerging candidates for detection. Compared to conventional tissue or cytology samples, liquid biopsy is non-invasive, safe, and easy to repeat. In view of tumor heterogeneity, it is also suggested that circulating cell free DNA may be more representative of the whole tumor cells population than a biopsy or cytology sample. In addition to assisting in the initial diagnosis, liquid biopsy can also be tailored for disease monitoring, detecting resistance mutation, tumor recurrence, and perhaps for screening in the future. The accuracy of this test is greatly facilitated by the advances of molecular techniques, from PCR-based methods, DNA sequencing, Digital PCR, to the more state-of-the-art next generation sequencing technologies. Despite the tremendous potential of liquid biopsy, there are limitations and not all clinical relevant cancer biomarkers can be detected in liquid biopsy at the present moment. The clinical utility of many of the tests derived from liquid biopsy required further investigations and clinical validation. This review provides an overview of the concept of liquid biopsy, its clinical applications, and discuss the multifaceted advances in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.